These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7884670)

  • 1. A double Weibull input function describes the complex absorption of sustained-release oral sodium valproate.
    Bressolle F; Gomeni R; Alric R; Royer-Morrot MJ; Necciari J
    J Pharm Sci; 1994 Oct; 83(10):1461-4. PubMed ID: 7884670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
    Wangemann M; Retzow A; Vens-Cappell B
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Weibull distribution model for intradermal administration of ceftazidime.
    Bressolle F; Laurelli JM; Gomeni R; Bechier JG; Wynn NR; Galtier M; Eledjam JJ
    J Pharm Sci; 1993 Nov; 82(11):1175-8. PubMed ID: 8289137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of food intake on the pharmacokinetics of a sustained release formulation of sodium valproate.
    Royer-Morrot MJ; Zhiri A; Jacob F; Necciari J; Lascombes F; Royer RJ
    Biopharm Drug Dispos; 1993 Aug; 14(6):511-8. PubMed ID: 8218969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of food on the pharmacokinetics of a new multiple unit sustained release sodium valproate formulation.
    Retzow A; Vens-Cappell B; Wangemann M
    Arzneimittelforschung; 1997 Dec; 47(12):1347-50. PubMed ID: 9450162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absorption of valproic acid suppositories in human volunteers.
    Holmes GB; Rosenfeld WE; Graves NM; Remmel RP; Carlson GH; Kriel RD
    Arch Neurol; 1989 Aug; 46(8):906-9. PubMed ID: 2502974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study on the dose proportionality of the pharmacokinetics of sustained release sodium valproate.
    Wangemann M; Retzow A; Mazur D; Vens-Cappell B
    Int J Clin Pharmacol Ther; 2000 Aug; 38(8):395-401. PubMed ID: 10984013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
    Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
    Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans.
    Bialer M; Hussein Z; Dubrovsky J; Raz I; Abramsky O
    Isr J Med Sci; 1984 Jan; 20(1):46-9. PubMed ID: 6421770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug : as shown by once-daily divalproex-ER.
    Dutta S; Reed RC
    Clin Drug Investig; 2006; 26(12):681-90. PubMed ID: 17274675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
    Dulac O; Alvarez JC
    Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications.
    Dutta S; Reed RC; O'Dea RF
    Ann Pharmacother; 2006 Apr; 40(4):619-25. PubMed ID: 16569797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a Level A in vitro-in vivo correlation (IVIVC).
    Dutta S; Qiu Y; Samara E; Cao G; Granneman GR
    J Pharm Sci; 2005 Sep; 94(9):1949-56. PubMed ID: 16052544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single dose and steady state pharmacokinetics of valproic acid in adult epileptic patients.
    Miljković B; Pokrajac M; Varagić V; Lević Z
    Int J Clin Pharmacol Res; 1991; 11(3):137-41. PubMed ID: 1809700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epilim chrono: a multidose, crossover comparison of two formulations of valproate in healthy volunteers.
    Roberts D; Easter D; O'Bryan-Tear G
    Biopharm Drug Dispos; 1996 Mar; 17(2):175-82. PubMed ID: 8907724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microminipig: A suitable animal model to estimate oral absorption of sustained-release formulation in humans.
    Hamada T; Watanabe Y; Iida K; Sano N; Amano N
    Int J Pharm; 2020 Jun; 584():119457. PubMed ID: 32464228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy.
    Rodrigues C; Chhun S; Chiron C; Dulac O; Rey E; Pons G; Jullien V
    Eur J Clin Pharmacol; 2018 Jun; 74(6):793-803. PubMed ID: 29564480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of valproic acid after administration of three oral formulations in healthy adults.
    Bano G; Gupta S; Gupta KL; Raina RK
    J Assoc Physicians India; 1990 Sep; 38(9):629-30. PubMed ID: 2266076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative bioavailability of different valproic acid formulations.
    Franke G; Diletti E; Hoffmann C; Zschiesche M; Scheuch E; Siegmund W
    Int J Clin Pharmacol Ther; 1995 Dec; 33(12):653-7. PubMed ID: 8963482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of repeated-dose activated charcoal on the pharmacokinetics of sodium valproate in healthy volunteers.
    al-Shareef A; Buss DC; Shetty HG; Ali N; Routledge PA
    Br J Clin Pharmacol; 1997 Jan; 43(1):109-11. PubMed ID: 9056061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.